Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- wang shusen
- Target Recruit Count
- 116
- Registration Number
- NCT05978648
- Locations
- 🇨🇳
Sun-yat sen university cancer center, Guangzhou, Gangdong, China
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 64
- Registration Number
- NCT05975307
- Locations
- 🇨🇳
Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, China
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
- Conditions
- Interventions
- First Posted Date
- 2023-07-19
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 20
- Registration Number
- NCT05952453
- Locations
- 🇺🇸
O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama, United States
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
- First Posted Date
- 2023-07-12
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Lan Coffman
- Target Recruit Count
- 30
- Registration Number
- NCT05942300
- Locations
- 🇺🇸
Magee-Womens Research Institute / UPMC Magee Womens Hospital, Pittsburgh, Pennsylvania, United States
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-03
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 2400
- Registration Number
- NCT05929768
- Locations
- 🇺🇸
Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Cancer Center of Kansas-Independence, Independence, Kansas, United States
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Istituti Clinici Scientifici Maugeri SpA
- Target Recruit Count
- 28
- Registration Number
- NCT05925491
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri, Pavia, Lombardia, Italy
Fasting Mimicking Diet (FMD) in Conjunction With Chemotherapy in Advanced Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- NorthShore University HealthSystem
- Target Recruit Count
- 170
- Registration Number
- NCT05921149
- Locations
- 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
A Study of PM8002 Injection in Combination With Standard Chemotherapy as First Line Therapy in MPM
- Conditions
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Biotheus Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT05918107
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 700
- Registration Number
- NCT05911295
- Locations
- 🇺🇸
Inova Schar Cancer Institute, Fairfax, Virginia, United States
🇧🇷Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos, Other, Brazil
🇧🇷Centro de Oncologia da Bahia, Salvador, Other, Brazil
Abequolixron (RGX-104) and Durvalumab in Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-06-22
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT05911308
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.